








Disease Monograph Series – 21 









Brucellosis | Monograph 21 














This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre    over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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AU  African Union 
AU-IBAR African Union Inter-African Bureau for Animal Resources 
BBAT  Buffered Brucella Antigen test 
BBSRC  Biotechnology and Biological Sciences Research Council 
BMGF  Bill and Melinda Gates Foundation 
CFT  Complement fixation test 
CI  Confidence Interval 
CVO  Chief Veterinary Officer 
DALY  Disability-adjusted life year  
DG  Director General 
DIVA  Differentiate infected from vaccinated animals 
DVS  Director Veterinary Services 
ELISA  Enzyme-linked immunosorbent assay 
FAO   Food and Agriculture Organization of the United Nations 
FPA  Fluorescence polarization assay 
IAEA  International Atomic Energy Agency of the United Nations 
IM  Intramuscular 
IN  Intranasal 
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NGO  Non-governmental organization 
OIE  World Animal Health Organization 
PCR  Polymerase chain reaction 
RBT  Rose Bengal test  
SC  Subcutaneous 
SHF  Small holder farmer 
SMP-AH Standard Methods and Procedures in Animal health Program 
TPP  Target Product Profile 
WHO  World Health Organization of the United Nations 
ZELS Zoonoses and Emerging Livestock Systems (Research initiative funded by DFID, BBSRC and 
others) 
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Disease, etiology, epidemiology and impacts 
Bacteria of the genus Brucella, are transmissible to a wide range of animal species. They cause Brucellosis, a 
widespread zoonosis consistently ranked among the most economically important zoonoses globally [1]. The 
most relevant species are Brucella abortus, B. melitensis and B. suis. The different Brucella species each have 
their host preference, but they are not host specific.  Brucellosis is mainly transmitted to humans from cattle, 
sheep, goats, pigs and camels through direct contact with blood, placenta, foetuses or uterine secretions, or 
through consumption of contaminated raw animal products (especially unpasteurized milk and soft cheese). B. 
melitensis has the highest zoonotic potential, but B. abortus and B. suis are also zoonotic and of public health 
relevance. 
In endemic areas, human brucellosis has serious public health consequences. Brucellosis affects approximately 
500,000 people annually worldwide. The disease is severely under-reported in humans, and acute febrile 
illnesses are often mistaken for malaria. Brucellosis is an occupational disease, and people in contact with 
animals, including smallholder farmers and abattoir workers, are at high risk. The reported incidence of human 
brucellosis ranges from less than 0.01 to more than 200 cases per 100,000 population [2]. The WHO estimates 
the DALYs due to Brucella spp is 264,073 and 2 DALYs per 100,000 persons.   
 
Incidence / Prevalence 
Brucellosis is endemic in many countries; it is not always a notifiable disease, and this contributes to explaining 
why the disease is underreported at national and at international levels.  In general terms, the number of 
outbreaks reported to the OIE and AU-IBAR, besides being discordant, seems to be below the number of 
outbreaks expected based on estimations of the observed herd prevalence and some of the publications 
available.   
The prevalence of brucellosis varies amongst countries, but also within regions and within species.  There are 
very limited data at national level. The majority of data is at regional level, and there is a publication bias; areas 
where certain Universities, NGOs or projects are active, seem to have more data - however, they might be 
working in that area because of the disease prevalence.  Much of the literature does not differentiate between 
B. abortus and B. melitensis. However, it is clear that B. melitensis is also a problem in cattle.  
 
Diagnostics 
Brucellosis can be diagnosed by culture, serology or other tests. According to the OIE Terrestrial Manual, no 
single serological test is appropriate in all epidemiological situations; all have limitations especially when it 
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comes to screening individual animals. In situations where vaccination with smooth Brucella is practised, false-
positive reactions may be expected among the vaccinated animals.   
For the control of brucellosis at the national or local level, the Buffered Brucella Antigen Tests (BBAT), i.e. the 
Rose Bengal Test and the Buffered Plate Agglutination test, as well as the ELISA and the Fluorescence 
polarization assay are suitable screening tests. Positive reactions should be retested using a suitable 
confirmatory and/or complementary strategy.  The prescribed tests for international trade are the BBAT, 
Complement Fixation Test and ELISA.  Dr Saxena in India has patented 2 innovative modifications to improve the 
sensitivity and specificity of the RBT, and is seeking partners for commercialization.  
Control 
Control, and in many cases eradication, of brucellosis has been achieved in many high and middle income 
countries. In some of them, it only continues to be a challenge in wildlife and feral animals. However, in many 
low and middle income countries control is very difficult. Treatment is not a viable option as it requires the 
combined use of different antibiotics for long periods of time. Control programs are based on vaccination.  
Usually when the prevalence is high, control is based on mass vaccination, and when the prevalence is low, a 
test/removal program is implemented.  Control at herd level might be possible, but regional and national 
programs are hard to implement when resources are scarce and the veterinary services are limited. 
 
Current vaccines for Brucellosis 
The vaccines recommended by the OIE are S19 for B. abortus in cattle, and Rev1 for B. melitensis in small 
ruminants.  However, the RB51 for B. abortus is also used, and it is the official vaccine in many countries.  S19, 
Rev1 and RB51 have been used widely worldwide. They are all live vaccines, and have many disadvantages. They 
are pathogenic for humans, induce abortion in pregnant animals, transmit to other animals and interfere with 
traditional Brucella diagnostics (RB51, and other vaccines given via the ocular route or at low dose interfere to a 
less extent). The vaccines are good at preventing clinical signs, but do not prevent infection or seroconversion.   
There is an obvious need for better vaccines that can overcome these issues.  There is also a great need for a 
better understanding of cross protection.  The cattle vaccines are all based on B. abortus, but B. melitensis is also 
a big problem in cattle. There is no consensus about the protection of the current B. abortus vaccines for B. 
melitensis in cattle, and the OIE does not recommend to use B. melitensis Rev1 vaccine in cattle. There is a need 
for a vaccine that confers good immunity in cattle for at least B. abortus and B. melitensis. 
There are vaccines other than S19, Rev1 and RB51 that have been used in specific areas or regions; for example, 
the B. abortus strain 82, and strain 75/79-AB (a dissociated form of strain 82) that have been used widely in the 
Russian Federation, Azerbaijan and Tajikistan.  In China, the B. melitensis M5 or M5-90 has been used in sheep 
and goats, as well as in cattle since the 1970’s.  Also in China, there is a commercial vaccine for B. suis, the strain 
2 vaccine.  The technical information publically available for these vaccines is limited, but they seem to have 
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been used successfully; it would be valuable to independently validate the claims that have been made in 
relation to these vaccines. A side by side comparison of the efficacy and cross-protection of the traditional S19, 
the low dose S19, but also 75/79 and M5 for B. melitensis in cattle, considering the inclusion of RB51 and Rev1, 
and any promising other candidates already tried in the target species, seems an obvious step.  
 
Potential new vaccines and the way forward 
As for new vaccines, there are several groups working on new candidates. Some are based on new technologies, 
while some are based on live bacterial mutants.  Due to limited availability of validated challenge models in 
target animals, many of the vaccines have been only tried in mouse models which are not ideal.  Results need to 
be interpreted carefully, as the practical value of a new vaccine is not a matter of short term protection, but long 
term protection, feasibility and cost.  A good candidate for B. melitensis seems to be the strain 16MΔvjbR which 
has been tried in different species. A very promising candidate for B. suis is the strain 353-1 vaccine which has 
already been tested in the target species (pigs) with good results.  Information for both of these candidates and 
any other promising vaccines, should be reviewed for scientific quality and other important considerations.  
As there is limited knowledge of the protective epitopes and antigens (some are known, but not all), it is unlikely 
that a vaccine based in a single epitope would be sufficient, a combination would more likely be needed.  
However, some vaccines based on combination of different Outer Membrane Proteins (OMP) seem promising. 
New delivery systems including nanotechnology, might be of particular use if the protective antigens were 
known.  
Characteristics of an ideal Brucella vaccine, can be seen under the Target Product Profile in Section 9. There 
might be commercial companies working on the development and improvement of Brucella vaccines, but there 
is no information publically available. AgResults, is planning to set up a prize mechanism for the development of 
new vaccines early in 2016.  
 
Commercial Brucellosis vaccines 
Commercial Brucella vaccine production in the countries of interest is limited.  For B. abortus, there are 
manufacturers in India and Indonesia of S19; there are B. abortus vaccines produced in other countries in the 
region like China or South Korea.  In Africa, B. abortus vaccines are produced in Egypt, Nigeria and South Africa. 
They all produce the S19 strain, while the RB51 is available in South Africa.  B. melitensis Rev1 vaccine is 
produced in India in Asia, and in Africa, it is manufactured in Egypt and South Africa.  Many of the countries that 
use vaccine, use imported vaccines.   
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New diagnostics or vaccines that allow differentiation of vaccinated from infected animals at any period after 
vaccination, and could be used in adult animals would be valuable.  They are not an urgent need, as many 
countries have achieved control with the currently available vaccines, which only allow differentiation of 
infected animals from vaccinated, when the animals are vaccinated at a young age. However, they require a 
solid surveillance program and good veterinary services. 
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Etiology & Epidemiology 
 
Brucellosis is caused by bacteria of the genus Brucella, a facultative Gram negative intracellular pathogen that 
affects most mammals. Six named species occur in animals: B. abortus, B. melitensis, B. suis, B. ovis, B. canis and 
B. neotomae. One or more unnamed species of Brucella have been found in marine mammals. Formal names 
proposed for marine mammal isolates are B. maris for all strains, or B. pinnipediae for strains from pinnipeds 
(seals, sea lions and walruses) and B. cetaceae for isolates from cetaceans (whales, porpoises and dolphins).  
Some species of Brucella contain biovars. Species and biovars can be identified by phage lysis, and by cultural, 
biochemical and serological criteria. Molecular methods have been developed that could also be used for 
complementary identification based on specific genomic sequences. Different biovars can have differences in 
host, pathogenicity, cultural and serological characteristics.  
The different Brucella species have their host preferences, but they are not host specific. There are many 
domestic and wildlife reservoirs. The presence of rough or smooth lipopolysaccharide is correlated to the 
virulence of the disease in humans. 
 
This monograph focus on B. abortus, B. melitensis and B. suis; it does not include B. ovis, B. canis or B. 
neomatae.  
• Brucella abortus affects mainly cattle, but other livestock and wild animals can be infected with varying 
susceptibility. Up to 9 biovars of B. abortus have been reported, but some differ only slightly. 
• Brucella melitensis predominantly affects sheep and goats but can also cause disease in other 
mammalian species.  There are 3 biovars of B. melitensis that show no difference in pathogenicity. 
Biovar 3 is the most commonly isolated. All breeds of goats are believed to be equally susceptible but 
resistance is assumed to vary in some breeds of sheep (Maltese sheep appear highly resistant, while 
certain fat-tailed breeds such as Awassi are highly susceptible).  
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• Brucella suis is the main cause of brucellosis in pigs. B. suis consists of 5 biovars. Pigs are infected by B. 
suis biovars 1, 2 or 3. The disease caused by biovars 1 and 3 is similar, while the one caused by biovar 2 
differs in pathology, host range, and it is limited to Europe.  B. suis biovar 2 is rarely pathogenic to 
humans, whereas biovars 1 and 3 are highly pathogenic and cause severe disease.   
The natural host and zoonotic potential for each Brucella species can be seen in Table 1.  
Table 1: Host preference for Brucella species in domestic animals.  Source: Byndloss and Tsolis. Brucella 






It is a highly contagious disease and is spread through contact with aborted foetuses, vaginal or uterine 
discharges following abortion or birth of infected offspring, placenta and milk. The uterine discharges and 
abortions are highly infections. Shedding is not constant.  The routes of transmission include ingestion of milk 
and contaminated materials, contact through mucous membranes, open wounds and conjunctiva.  
The disease in pigs differs by its prolonged bacteremia, ability to be venereally transmitted (transmission occurs 
mainly via semen), and prolonged shedding of B. suis from mucosal surfaces or in urine, even in males or non-
pregnant sows (which also appear capable of contributing to disease transmission). 
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Early bacteraemia is followed by localization of the infection particularly in the reproductive organs and cells of 
the monocyte-macrophage series.  
Animals 
The bacteria enters via invasion through mucous membranes and is localized in the reticuloendothelial system 
before septicemic spreads to other tissues.  The most important clinical manifestation is reproductive failure. 
Following localization in the pregnant uterus, the bacteria cause placentitis which can lead to abortion, retained 
placenta or birth of weak, Brucella-infected offspring. In both males and females, Brucella spp. can induce 
inflammatory responses in reproductive tissues that may lead to infertility or sterility.  It also produces reduced 
milk yields in females. Males may develop orchitis and epididymitis. Arthritis might develop in chronic infections.  
In cattle, B. abortus causes abortions, stillbirths and weak calves; abortions usually occur during the second half 
of gestation (cows infected at service abort after an average interval of 225 days, while those infected at 7 
months’ gestation, abort about 50 days later). In fully susceptible herds, abortion rates vary from 30 – 70%. The 
placenta may be retained after abortion, and when it is retained, metritis is common. Lactation may be 
decreased. After the first abortion, subsequent pregnancies are generally normal; however, cows may shed the 
organism in milk and uterine discharges.  
Epididymitis, seminal vesiculitis, uni- or bilateral orchitis and testicular abscesses are sometimes seen in bulls. 
Infertility occurs occasionally in both sexes, due to metritis or orchitis/epididymitis. Hygromas, particularly on 
the leg joints, are a common symptom in some tropical countries. Arthritis can develop after long-term 
infections. Systemic signs do not usually occur in uncomplicated infections, and deaths are rare except in the 
fetus or newborn. Infections in nonpregnant females are usually asymptomatic. Congenitally infected calves may 
remain sero-negative for at least 18 months, after which they may manifest the clinical signs. Similar symptoms 
occur in other ruminants including camels and water buffalo. 
B. melitensis mainly causes abortions, stillbirths and the birth of weak offspring. The first sign of the presence of 
the disease in a susceptible herd or goats or flock of sheep is usually an abortion storm during which a high 
proportion of the pregnant animals abort, usually late in gestation. Animals that abort, particularly nanny goats, 
may retain the placenta. Sheep and goats usually abort only once, but reinvasion of the uterus and shedding of 
organisms can occur during subsequent pregnancies. Milk yield is significantly reduced in animals that abort, as 
well as in animals whose udder becomes infected after a normal birth. However, clinical signs of mastitis are 
uncommon. Acute orchitis and epididymitis can occur in males, and may result in infertility. Arthritis is seen 
occasionally in both sexes. Many non-pregnant sheep and goats remain asymptomatic. Kids or lambs born from 
infected females may be born weak or are asymptomatic; it is thought that some of them may become 
persistent latent carriers.  
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In pigs, the most common symptoms of B. suis are abortion, which can occur at any time during gestation, and 
weak or stillborn piglets. Vaginal discharge is often minimal and abortions may be mistaken for infertility. 
Occasionally, some sows develop metritis. Temporary or permanent orchitis can be seen in boars. Boars can also 
shed B. suis asymptomatically in the semen; sterility may be the only sign of infection. Swollen joints and tendon 
sheaths, accompanied by lameness and incoordination, can occur in both sexes. Less common signs include 
posterior paralysis, spondylitis and abscesses in various organs. Although some pigs recover, others remain 
permanently infected. Fertility can be permanently impaired, particularly in boars. Some animals remain 
asymptomatic. Some piglets infected in utero may die within a few hours of birth, the mortality rate often being 
very high, but others survive and retain the infection into adulthood.  
Humans 
Brucella sp. causes a flu-like febrile syndrome including intermittent and relapsing fever, body aches, joint pain, 




Brucellosis can be diagnosed by culture, serology or other tests. Unequivocal diagnosis of Brucella infections can 
be made only by the isolation and identification of Brucella, but in situations where bacteriological examination 
is not practicable, diagnosis must be based on serological methods. There is no single test by which a bacterium 
can be identified as Brucella. A combination of growth characteristics, serological, bacteriological and/or 
molecular methods is usually needed. 
According to the OIE Terrestrial Manual, no single serological test is appropriate in all epidemiological situations; 
all have limitations especially when it comes to screening individual animals. Consideration should be given to all 
factors that impact on the relevance of the test method and test results to a specific diagnostic interpretation or 
application. In situations where vaccination with smooth Brucella is practised, false-positive reactions may be 
expected among the vaccinated animals because of antibodies cross-reacting with wild strain infection. The 
serum agglutination test (SAT) is generally regarded as being unsatisfactory for the purposes of international 
trade. The complement fixation test (CFT) is diagnostically more specific than the SAT, and also has a 
standardised system of unitage. The diagnostic performance characteristics of some enzymelinked 
immunosorbent assays (ELISAs) and the fluorescence polarisation assay (FPA) are comparable with or better 
than that of the CFT, and as they are technically simpler to perform and more robust, their use may be 
preferred.  
 
OIE recognized tests 
a) Identification of the agent:  
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• Bacteriology (staining, culture) and confirmation by PCR 
• Nucleic acid detection: PCR 
b) Serology and allergy skin reaction: 
• Buffered Brucella Antigen test (BBAT): Rose Bengal (RBT) and Buffered plate 
Agglutination test (BPAT) 
• Complement Fixation test (CFT) 
• ELISA 
• Fluorescence polarization assay (FPA) 
• Brucellin skin test (not very common) 
c) Milk tests: (used to test milk from the bulk tank) 
• Milk I-ELISA 
• Milk ring test 
• Most commonly used in low & middle-income countries: 
a) National laboratory: will depend if the laboratory has access to the reagents for BBAT. ELISA is 
also used.  
b) For the control of brucellosis at the national or local level, the BBAT, i.e. the RBT and the BPAT, 
as well as the ELISA and the FPA are suitable screening tests. Positive reactions should be 
retested using a suitable confirmatory and/or complementary strategy.  The prescribed tests for 
international trade are the BBAT, CFT and ELISA.  
• Cross reactions with Yersinia enterocolitica O:9 should be considered as they are almost 
indistinguishable from true brucellosis serological reactions.  
• Recent developments:  Dr Saxena (College of Veterinary Science, Guru Angad Dev Veterinary & Animal 
Sciences University (GADVASU), Ludhiana, India), has introduced two innovative modifications to the 
RBT, to produce a more sensitive and specific test called “Superagglutination”. See Section 7 for more 
details.  
• Main needs for diagnostics: 
a) A sensitive test that could be used to differentiate infection from vaccination, even for animals 
vaccinated with the most commonly used vaccines, namely S19 or Rev1.  
b) A diagnostic test that could be used at the point of care by Primary Animal Health Care (PAHC) 
providers.  
c) Commercial kits: Cheaper kits, and kits that don’t require cold storage.  
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d) There are no commercially available PCR kits that claim to diagnose brucellosis. 
 
Zoonotic disease 
Worldwide, Brucella melitensis is the most prevalent species causing human brucellosis, owing in part to 
difficulties in immunizing free-ranging goats and sheep. B. melitensis causes Malta fever (also called 
Mediterranean or undulant fever) and it is one of the most important zoonoses.  Brucellosis in humans is also 
caused by B. abortus and B. suis, resulting in a disease very similar to the one caused by B. melitensis (see Table 
1).  
In humans, consumption of raw milk and cheese made from raw milk is the major source of infection. Brucella is 
also transmitted by direct contact with infected animals, animal carcasses and aborted material. 




Brucella triggers both antibody and cell-mediated responses. In primary infections, antibodies are not effective, 
and overcoming the infection depends largely on the cellular immune response. Antibodies, however, may play 
a role in the protection provided by vaccines and when transferred via colostrum and milk. 
Brucella can invade and persist in macrophages that are in a non-activated state at the time of entry but do not 
seem to survive in pre-activated macrophages. The route of entry into these cells is therefore important. The 
infective strategy of brucellosis is believed to be one of stealth whereby it establishes itself into its favoured 
niche prior to the host raising an effective immune response. The host may respond by increasing the 
inflammatory action of macrophages but this may come too late and lead to a failure of clearance that results in 
the recurrent febrile episodes seen in humans. 
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B. abortus is found worldwide in cattle-raising regions, except in Japan, Canada, some European countries, 
Australia, New Zealand, and Israel, where it has been eradicated. Eradication from domesticated herds is nearly 
complete in the USA. B. abortus persists in wildlife hosts in some regions, including the Greater Yellowstone 
Area. 
B. melitensis is particularly common in the Mediterranean. It also occurs in the Middle East, Central Asia, around 
the Arabian Gulf, and in some countries of Latin America. This organism has been reported from Africa and 
India, but it does not seem to be endemic in northern Europe, North America (except Mexico), Southeast Asia, 
Australia, or New Zealand. There have been annual incidence reports of up to 78 cases per 100,000 people in the 
Mediterranean and Middle East. However, more than 550 cases have been reported from confined endemic 
areas in the Mediterranean and Middle East that have no mandatory animal control measures. In some 
countries where animals are controlled, such as Southern Europe, an annual incidence of 77 cases per 100,000 
has been reported. Infection levels can be much higher, for example, a seroprevalence rate of 20% was 
identified on the Arabic Peninsula, with greater than 2% having active brucellosis.  
 
Information available: 
• OIE information: Data of outbreaks reported to the World Animal Health Organization (OIE) are not always 
reliable, as many countries doesn’t seem to report, or to be reporting consistently over time.  
(http://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Countrytimelines). McDermott in 
2013 [1] showed that the number of predicted brucellosis cases per year compared the number of outbreaks 
reported to the OIE falls well below the number that can be expected based in the disease prevalence as 
shown in Table 2 below.   
• AU-IBAR: The African Union Inter-African Bureau for Animal Resources also has a notification system. Data are 
published in the Pan African Animal Resources Year Books. Similarly to the OIE, many countries do not seem 
to consistently report the outbreaks.  
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• Peer reviewed publications and grey literature:  Information for the different countries can usually be found 
in peer-reviewed publications or grey literature (for example Theses) on the internet. They usually contain 
data that concern a regional area, and not at national level.  
 
• Systematic review: A very good source is a recent publication from McDermott [1], in which building on a 
previous ILRI report, they assessed 259 recent studies (period range not specified), to develop maps showing 
the prevalence estimates for brucellosis in the different species. The maps for brucellosis prevalence in cattle, 
small ruminants and humans can be seen below.  
 
Table 2: The number of predicted brucellosis cases per year compared to the number of outbreaks reported 








Figure 1: Results of a systematic review showing brucellosis prevalence estimates in cattle on a map of 
livestock production systems in Asia and Africa. Source: McDermott, 2013 [1]. 
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Figure 2: Results of a systematic review showing brucellosis prevalence estimates in small ruminants and 





Figure 3: Results of a systematic review showing brucellosis prevalence estimates in humans on a map of 
livestock production systems in Asia and Africa. Source: McDermott, 2013 [1]. 
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A more recent review in Africa, has been conducted by Boukary in 2014 [3].  The map in Figure 4 below shows the 
prevalence of bovine brucellosis in Africa based on the publications between 1995 and 2009 and the human 




Figure 4: Prevalence of bovine brucellosis in Africa, based on publications between 1995 and 2009. Source: 




Incidence data by country 
There are two main sources, OIE and AU-IBAR.  Data are not similar.  
1- Source: OIE.  http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail 
Please note previous remark made on OIE information (page 7).  Similar information but presented in a different 
manner can be seen in Annex 1.   
Number of cases reported to the OIE by disease and by country: 
     -   No information,      +   Present but quantitative data not known,   ?  Disease suspected 
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Brucella abortus incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - - + + + + + + - - 
India - 6 + 3 4 10 2 5 7 7 - 
Indonesia - + + + + + + + 32 - - 
Myanmar - 3 14 1 10 3 1 0 7 3 - 
Nepal - 0 0 0 0 0 ? 0 0 1 0 
Vietnam - ? ? ? ? ? ? ? ? ? 0 
 
Brucella melitensis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - 0 0 0 + + + 0 - -- 
India - - - - - - - - - - - 
Indonesia - - - 0 - - - - - - - 
Myanmar - - - 0 0 1 - 1 0 1 - 
Nepal - 0 - - - - - - + 0 0 
Vietnam - - - - - - - - - - - 
 
Brucella suis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Bangladesh - - 0 0 0 0 0 0 - - - 
India - - - - - - - - - - - 
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Indonesia - - - 0 - - - - - - - 
Myanmar - - - 0 0 0 0 0 0 0 - 
Nepal - - - - - - - - - - - 
Vietnam - - - - - - - - - - - 
 
WEST AFRICA 
Brucella abortus incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso - + + + + + + 0 + + + 
Ivory Coast - + >1 + + + + + + - - 
Mali - + + - +? - - - - - - 
Senegal - - - - - - - ? ? ? ? 
 
Brucella melitensis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso - - - - - - - - - - - 
Ivory Coast - - - - - - - - - - - 
Mali - 0 - - +? - - - - - - 
Senegal - - - - - - - - - - - 
 
Brucella suis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso - - - - - - - - - - - 
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Ivory Coast - - - - 0 0 0 0 0 - - 
Mali - 0 - - - - - - - - - 
Senegal - - - - - - - - - - - 
 
EAST AFRICA: 
Brucella abortus incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Ethiopia - 0 + + + + + + ? 0 - 
Kenya - 9 24 4 21 11 7 8 10 12 6 
Rwanda - + - - - - - - 12 - - 
Tanzania - +? +? + + + 1 + 1 + + 
Uganda - 8 11 + + + 17 8 + + - 
 
Brucella melitensis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Ethiopia - 0 0 0 0 2 + 0 ? 0 - 
Kenya - - - 0 0 0 0 0 0 0 0 
Rwanda - 0 - + ? ? ? ? ? - - 
Tanzania - - - 0 - - - - - - - 
Uganda - 2 5 2+ + + + + + + - 
 
Brucella suis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Brucellosis | Monograph 21 






Ethiopia - - - - 0 0 0 0 0 0 - 
Kenya - - - 0 ? 0 0 0 0 0 0 
Rwanda - 0 + + ? 0 0 0 0 - - 
Tanzania - - - 0 0 0 0 0 0 - - 
Uganda - - ? ? 0 0 0 0 0 0 - 
 
SOUTHERN AFRICA: 
Brucella abortus incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Madagascar - 0 0 0 0 0 0 0 0 0 - 
Malawi - - - - - - - - - - - 
Mozambique - 12 13 9 22 12 8 11 15 9 - 
South Africa - 309 356 327 413 338 276 291 264 335 - 
Zambia - - 3 13 22 14 + 13 13 19 - 
 
Brucella melitensis incidence (number new outbreaks reported) 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Madagascar - 0 0 0 0 0 0 0 0 0 - 
Malawi - - - - 0 0 0 - - - - 
Mozambique - - 0 0 0 0 0 0 0 0 - 
South Africa - 0 1 0 0 1 0 0 0 0 - 
Zambia - - ? ? ? ? ? ? 0 0 - 
 
Brucella suis incidence (number new outbreaks reported) 
Brucellosis | Monograph 21 






Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Madagascar - 0 0 0 0 0 0 0 0 0 - 
Malawi - 0 0 0 0 0 0 0 - - - 
Mozambique - - - - + 0 0 0 0 0 - 
South Africa - 0 0 0 0 0 0 0 0 0 - 
Zambia - - - - 0 0 0 0 0 0 - 
 
The OIE, also includes zoonoses data. The number of human cases and deaths are reported by the countries. 
Data from the countries of interest, can be seen in the table below.  
http://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Zoonoses  
 
Human cases and deaths due to Bovine TB as reported to the OIE 
 
 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Bangladesh
India
Indonesia C: +, D: +
Myanmar C: +, D: +
Nepal C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Vietnam C: +, D: + C: +, D: + C: 35, D: 0
Burkina Faso C: +, D: + C: +, D: +
Ethiopia C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Ivory Coast C: +, D: +
Kenya C: 66, D: 5 C: 4,585, D: 0 C: +, D: + C: +, D: + C: 84,775, D: 0 C: 96,571 D: 0
Madagascar
Malawi C: +, D: +
Mali C: +, D: +
Mozambique C: +, D: + C: +, D: + C: +, D: +
Rwanda C: +, D: + C: +, D: + C: +, D: + C: +, D: +
Senegal
South Africa C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: 26 C: +, D: + C: +, D: + C: 1
Tanzania C: +, D: + C: +, D: + C: +, D: + C: +, D: + C: +, D:+
Uganda C: +, D: +
Zambia C: +, D: +
C: Cases
D: Deaths
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2- Source: AU-IBAR. 
Number of outbreaks per year as reported to AU-IBAR and published in the Pan African Animal Resources 
YearBook. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=)  
Note that there is not distinction between the different types of Brucellosis. Interestingly, the number of 
outbreaks reported often does not match those reported to the OIE. NS= Not specified  
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Burkina Faso            
Ethiopia      2      
Ivory Coast 1 2          
Kenya  1  12 NS NS  3 1 4  
Madagascar            
Malawi            
Mali            
Mozambique 8 15 12 28 21 17 19  22 21  
Rwanda            
Senegal        1 1   
South Africa 346 336 618 605 144 394 282 680 634 560  
Tanzania 1  4    1  1   
Uganda  6 6 2 19 6 29 10 16 15  
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Prevalence data by country 
• Sources: PubMed, Brucella 2014 International Research Conference proceedings, and internet engine 
searches (English and French when applicable).   
• Efforts have been made to include the year of the study, and not the year of the publication. If they are 
known to be different, the year of publication is included in the reference.  
• For grey literature, links have been included when possible.   
• Note that not all papers have been read in full. In many cases, only the abstracts have been read. Critical 
evaluation of the papers for inclusion has not been conducted.  If a review paper included some references, 




Ruminants: Most recent review for ruminants, is a PhD thesis from Rahman in 2015 [4]. It contains good detailed 
tables, summarising the literature review for several years (shown below).  His own work in Dhaka and 
Mymensingh districts concludes that true exposure prevalence of brucellosis in cattle under small-scale dairy 
and subsistence management systems is very low (0.3%).  The prevalence was high (20%) in the Central Cattle 
Breeding and Dairy farm. The true exposure of brucellosis in goats and sheep were also low (1%).  
Pigs: The first published report was in 2012 [5]. 105 sera form 2 districts (Sirajganj and Bogra) were analysed, and 
7 (6.7%) and 5 (4.8%) were found to be positive by RBT and SAT respectively.  
Humans: True prevalence from Mymensingh district in high risk occupationally exposed people have been found 
at 4.4% and in pyretic patients at 2.7% [4]. Only B. abortus was identified.  
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Reported seroprevalence of brucellosis in cattle in Bangladesh. Source: Rahman, 2015 [4].  
 
Reported seroprevalence of brucellosis in cattle in Bangladesh - milk ring test. Source: Rahman, 2015 [4] 
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Reported seroprevalence of brucellosis in goats and sheep in Bangladesh. Source: Rahman, 2015 [4]. 
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Ruminants: There exists a wide variation in different reports on prevalence of brucellosis in animals. The table 
below shows a summary of the data.   
References:  The ones marked * were referenced by Dr Singh Sharma at a presentation during the FAO Regional 
Workshop on brucellosis diagnosis and control in Asia-Pacific region, 2014 (http://www.rr-
asia.oie.int/fileadmin/Regional_Representation/Programme/Emerg/2014_Brucellosis_Chiang_Mai/05.India.p
df) but haven’t been able to find the original reference.  
Year Area Species of animal No. of 
samples 
tested 
% positive Reference 
2014 Kolkata Cattle 988 RBT: 4.85 
ELISA: 5.46 
Chakraborty et al [6] 
2013 Punjab and Hariyana  Cattle and buffalo (dairy 
animals) 
 26.5 Chand and Chhabra [7] 
2011 Maharashtra   40.4 Lodhe* 
2010 Organized dairy 
farms  
Dairy animals (Cattle and 
buffalo) 
 13.7 Trangadia, Rana et al 
[8] 
2009  Yak  21.11 Bandyopadhayay, 
Sasmal et al [9]  








Maher Sulima et al* 
2005 Punjab  Different species of 
animals 
973 11.23 Dhand, Gumber et al 
[10] 
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2004 Nagaland Mithun (Indian Bison) 98 ELISA: 34 
STAT: 20 
RBT: 11 
Rajkhowa, Rahman et 
al [11] 








1998 Surveillance in 23 
states of India 
Cattle and buffalo 30,437 Cattle: 1.9  
Buffalo: 1.8 
Isloor, Renukaradkya 
et al [13] 
1985 Bikaner district Milk goats  11.45 Kappor et al* 
1984 Nagpur Bovine 953 9.7 Nawathe and Bhagwat 
[14] 


















Sharma, Sethi et al [15] 
 
Pigs:  Very limited data, but already identified in 1979 (see table above) 
Nagaland:  3 animals tested positive out of 53 (5.6%) by using the Brucella IfG flow assay [16] 
Humans:  The table below shows a summary of the data.  
References:  The ones marked * were referenced by Dr Singh Sharma at a presentation during the FAO Regional 
Workshop on Brucellosis diagnosis and control in Asia-Pacific region, 2014 (http://www.rr-
asia.oie.int/fileadmin/Regional_Representation/Programme/Emerg/2014_Brucellosis_Chiang_Mai/05.India.p
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Year Place of 
study 









2011 South India   68  Sathyanarayanan, Razak et 
al [17] 
2011 Pujab Blood of occupationally 
exposed group tested 
by PCR 
116 8 7 Gemechu, Gill et all [18] 





26948 517 1.9 Mantur [19] 
2004 Bijapur, 
Karnatka 
Brucellosis in child 5726 93 1.6 Mantur [20] 
2003 Bikaner   98  Kochar, Sharma et al [21] 
2002  Chronic brucellosis  28 6.8 Sen et al* 
2000 Kashmir Patients with fever of 
unknown origin over a 
period of 5 years 
3532 28 0.8 Kadri, Rukshana et al [22] 
1998 India Patients with fever of 
unknown origin 
121 12 9.9 Handa, Singh et al [23] 
1998 India Occupationally 
exposed individuals 
50 7 14 Handa, Singh et al [23] 
1979 UP and Delhi  1685  0.89 Sharma, Sethi et al. [15] 
 
Data in Punjab state:  
Dr Singh Sharma at a presentation during the FAO Regional Workshop on Brucellosis diagnosis and control in 
Asia-Pacific region, 2014 (as per links mentioned above) 
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Ruminants: Serological investigation of Brucella infection in beef cattle tended under extensive farming 
conditions in Bali, revealed a high seroprevalence (19.3%; 95% CI, 17-22) in the compliment fixation tests [24]. 
Data from samples tested for Bovine Brucellosis at the Disease Investigation Centre (DIC) Maros. Modified from 





Year Samples Positive % 
2011 3524 1097 31.13 
2012 5794 942 16.26 
2013 5099 697 13.67 
 
Pigs: Data from 1988 showed Brucella suis biotype 1 was isolated from 13.1% of the pigs slaughtered in Kapuk 
Jakarta, West Java and from 15.09% of the pigs slaughtered in Surabaya, East Java [25]. The prevalence of B. suis 
by means of the Rose Bengal Plate Test, was 22.3% for West Java and 14.9% for East Java. The Rose Bengal Plate 
Test detected more B. suis infected animals (73% of the infected animals) than did the Complement Fixation 
Test (41%) and the Serum Agglutination Test (54.5%).  
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Very limited information is available from Myanmar (or Burma).   
1977: A WHO report posted online (http://apps.who.int/iris/bitstream/10665/156172/1/sea-hlm-137.pdf) by 
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The only other source that was found, is an MSc Thesis from 2007, which focus in dairy cattle in Yangon. 
Prevalence on farm level was estimated at 3.83%, and on animal level at 0.47% [26]. 
Source: Prevalence survey of bovine brucellosis (Brucella abortus) in dairy cattle in Yangon, Myanmar. Thesis by 
Than Naing Tun, Master of Veterinary Public Health, 2007 – Ref 26. 
 
Nepal 
Animals: The table below shows a summary of the information for the different species in Nepal. 
Sources: 
*: As mentioned on the presentation by Dr Pragya Koirala at the FAO Regional workshop on brucellosis diagnosis 




**: http://www.amazon.com/Seroprevalence-Brucellosis-Different-Species-Animals/dp/3844399577  
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Year Area Species of animal No. of samples 
tested 
% positive Reference 










Pandeya et al [28] 
2008 Different parts 
of Nepal 








2000  Cattle and buffalo  1.25 Joshi [29] 
2000 Milk collection 
area of DDC 
Goats 558 4.5 Joshi* 
1997  Water buffalo, cattle 
and sheep 





1996 Chitwan Dairy cattle 91 3.3 Pradhan* 
1993  Cattle, buffalo, goats  Cattle: 1.28 
Buffalos: 1.93 
Goats: 3.7 
Jha et al* 
1983 Kathmandu 
valley 
Cattle, buffalo, sheep 
and goats 
Cattle & buffalo: 
1069 
Sheep and goats: 
247 
Cattle & buffalo: 
8.7% 
Sheep and goats: 
3.64 
Joshi* 




Humans: Dr Joshi reported in 1983 a human prevalence in the Kathmandu valley of 6.08% (87/1430).  In 2000, 
he found a prevalence of 4.5%  [29]. In another study by Aryal in 2007, the prevalence was recorded 11.93% [30]. 
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Ruminants and pigs:  According to the data presented by Dr Nguyen Khanh Ly at the FAO Regional workshop on 
brucellosis diagnosis and control in Asia-Pacific region, there was no evidence of the disease. They tested dairy 
cattle: 285 animals in 2011, 88 in 2012 and 70 in 2013.    
http://www.rr-
asia.oie.int/fileadmin/Regional_Representation/Programme/Emerg/2014_Brucellosis_Chiang_Mai/15.Vietna
m.pdf.   
The disease has never been reported to OIE.  However there was evidence of the disease in 1962 
(http://www.cabdirect.org/abstracts/19632702734.html;jsessionid=3F86F2AFEAF4956A1221DC4DECAA4CB5)
. 
Humans: In 2006, in Binh Thuan province, the seroprevalence in the Rose Bengal test among 406 patients 
presented with acute undifferentiated fever was 14.8%. Seven of the 64 Rose Bengal test positive samples 




Animals:     
Year Area Species of animal No. of samples 
tested 
% positive Reference 
2013 Transhumant 
cattle 
Cattle 464 7.3 Dean et al [32] 
2009  Cattle 273 16.42 Boussini et al* 
2004-
2005 
Ouagadougou Cattle 1689 3.61 Boussini et al [33] 
2001-
2002 
Hamdallaye Cattle 290 13.2 Traore et al, 2004 
[34]  
2000 Peri-urban Cattle 1107 8 Coulibaly et al [35] 
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*Source: Akuku, I. Brucellosis in Africa. Paper given at the Workshop “An integrated approach to controlling 
brucellosis in Africa”. Ethiopia, 2013 [36]. 
Humans: Data from 1976 established a 10% prevalence in an agro-pastoral area of Burkina Faso [37]. 
 
Côte d'Ivoire (Ivory Coast) 
Animals:  Recent data are shown in the table below.  
In a recent presentation by Dr. Kanoute, the data is not clear, but it concludes that Brucellosis seems to be an 
important zoonosis in small ruminants in Korhogo, and it is more likely to be B. melitensis. 
http://www.csrs.ch/Africa2013/PDF/090_Kanoute_Youssouf.pdf 
 
Year Area Species of animal No. of samples tested % positive Reference 
2012 Savannah-
forest region 
Cattle 907 10.3 Sanogo et al [38] 
2008 Pastoralist Cattle 660 8.8 Sanogo et al* 
2004 Abidjan Cattle Private dairy farms: 
244 
Traditional: 137 
Private dairy: 3.6 
Traditional: 4.3 
Thys et al [39] 
 
*Source: As referenced by Boukary, 2014 [3]. 
*Source: As referenced by Akuku, I. Brucellosis in Africa. Paper given at the Workshop “An integrated approach 
to controlling brucellosis in Africa”. Ethiopia, 2013 [36]. 
• Humans: Data from the north region of Korhogo and the west region of Odienne from studies by Gidel found 
a prevalence of 7-8% - no year given [36]. 
 
Ethiopia 
Dairy cattle:  There is a very good and recent Meta-analysis review of the prevalence of brucellosis in dairy cattle 
by Asmare [40]. The summary of the prevalence is shown in the table below.  
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Additional information and other reports are summarised below:     
Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 
2012 Southern and central  Goats 3315 Sedentary: 0.6 
Agro-pastoral: 1.9 
Pastoral: 7.6 
Asmare et al* 
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2011 Hammer and 
Dasenech (South 
Omo) 
Goats 384 4.2 Ashagrie et al* 
2011 Somali Cattle  Shinle: 42.9 
Jijiga: 50 
Megersa et al* 








Megersa et al* 
2010-
2011 
Dire-Dawa (Eastern) Camel 646 2 Warsame et al* 
2010-
2011 
Guto-Gida (Oromia) Cattle 406 3 Yohannes et al* 
2012  
2010 Sidama (Southern) Indigenous 
zebu 
1627 Individual: 1.6 
Herd level: 13.7 
Asmare et al* 
2010 Peri-urban Awassa Cattle  3.9 Abebe* 
2010 Arsi-Negele (Oromia) Cattle 400 Individual: 2.6 
Herd level: 12 
Amenu et al* 
2010  Cattle  Individual: 3.1 
Herd: 15 







370 0.5 Degefa et al*, 2011 







2009 Oromia Cattle 1106 Pastoral: 15.2 
Agro-pastoral: 4.1 
Dinka & Chala* 
2009 Central Oromiya Cattle  Individual: 2.9 Jergefa et al*** 
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Herd level: 13.6 
2008-
2009 


















Sheep 800 1.5 Yesuf et al* 2011 

















Amhara Cattle 780 RBT: 1.28 
CFT: 0.5 
Tedele et al* 
2007 Tigray Indigenous 
cattle 
816 Individual: 3.3 
Herd level: 42.3 
Berhe et al*** 






Ashenafi et al** 







2007 North western 
Amhara 
Cattle  4.63 Mussie et al*** 
2007 Sidama (Southern) Cattle  2.46 Kassahun et al *** 
2006 Pastoral Sheep and 
goats 
2000 RBT: 1.9 
i-ELISA: 9.7 
Teshale et al 
2006 Southeast Somali Camels 822 Individual: 2.43 
Herd level: 10.3 
Birhanu*** 
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2005 Afar region Sheep and 
goats 
 Sheep: 15 
Goats: 16 
Yibeltal et al*** 
2005 Borena lowlan Camels 3218 1.8 Megersa et al*** 
2003 Afar, Somali and 
Borena 
Camels 1442 RBT: 5.6 
CFT: 4.2 
Teshome et al** 
2002 Borena (Oromia) Cattle  50 Alem and 
Solomon*** 
 
*Source: Akuku, I. Brucellosis in Africa. Paper given at the Workshop “An integrated approach to controlling 
brucellosis in Africa”. Ethiopia, 2013, Ref 36. 
**Source: As referenced by Boukary, 2014 [3]. 
***Source: As referenced by Yohannes, 2013 [41]. 
Humans:  
Year Area Remarks No. of samples 
tested 
% positive Reference 
2009 Northern 
Ethiopia 
Patients with acute fever 653 Finotesalam: 6.3 
Quarit: 3 
Bembecha and Jiga: 0 
Abebe et al* 
2009  Traditional pastoral 
communities. Patients 
with febrile illness  
 Borena: 34.1 
Hammer: 29.4 
Metema: 3 
Ragassa et al* 
2007 Amhara High risk groups 238 5.3 Mussie et al 
2007 Sidama High risk groups 38 3.78 Kasahun et al* 
2007  Fever of unknown origin 56 3.6 Tolosa et al* 
2006 Addis Ababa High risk groups 336 4.8 Kassahun et al* 
*Source: As referenced by Yohannes, 2013 [41]. 
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Animals:     
Year Area Species of animal No. of samples 
tested 
% positive Reference 
2014 Kajiado and 
Kiambu 










Ogola et al [42] 









2012 Kiambu (Kajiado 
and Kiambo) 
Various Cattle: 1303 
Goats: 310 
Sheep: 455 
Herd level: 6 Kenya Zoonotic 
Disease Unit** 
2009 Eldoret Dairy cattle 130 milk samples 0 Namanda et 
al*** 





 Cattle: 0.9 
Small ruminants: 1 
Pigs: 0.9 
Akakpo et al [43] 
2007 Dagoretti Cattle 393 1 Kang’ethe et 
al**** 









Raw milk: 5 
Informal market milk: 
2.4-3.4 
Kang’ethe et al 
[44] 
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*Source: Kosgein et al. 2014. Estimating prevalence in livestock and assessment of knowledge, attitudes and 
practices of respective communities in Baringo County, Kenya. Research application summary.  
http://www.ruforum.org/sites/default/files/Kosgei.pdf 
**Source: http://zdukenya.org/wp-content/uploads/2012/09/Brucellosis-study_Kiambu.pdf  
***Source: Akuku, I. Brucellosis in Africa. Paper given at the Workshop “An integrated approach to controlling 
brucellosis in Africa”. Ethiopia, 2013 [36]. 
****Source: As referenced by Boukary, 2014 [3]. 
Humans:  
Year Area Remarks No. of samples 
tested 
% positive Reference 
2014 Kiambu and 
Kajiado 












Ijara  Febrile patients at Ijara 
District Hospital 
384 Seroprevalence: 31.8 
PCR: 15.4 
Kiambi, 2012* 
2000 Pastoralist area Patients with flu like 
symptoms 
488 13 Maiachomo et 
al ** 
*Source: Prevalence and factors associated with Brucellosis among febrile patients attending Ijara District 
Hospital, Kenya. MSc thesis by Stella Gaichugi Kiambi, 2012.  
http://elearning.jkuat.ac.ke/journals/ojs/index.php/pgthesis_abs/article/view/208/173) 
**Source: As referenced by Akuku, 2013 [36].  
 
Madagascar 
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No published information has been found confirming the presence of brucellosis in livestock. There have no 
been official reports, so the disease might not be present.  
 
Malawi 
Animals:  There is only very limited recent information about brucellosis in Malawi: 
Year Area Species of animal No. of samples 
tested 
% positive Reference 
2011 Northern 
region 
Dairy cattle 156 Mzimba: 8.1 
Nkhata: 6.3 
Tebug et al [45] 
 
Mali 
Animals: There are no recent publications.  
Year Area Species of animal No. of 
samples 
tested 
% positive Reference 
1995 Mixed areas Cattle 867 19.7 Maiga et al* 
1994 Different areas Cattle  9466 Individual: 22 




Tounkara et al [46] 
*Source: As referenced in Boukary, 2014 [3].  
 
Humans:  
Year Area Remarks No. of samples 
tested 
% positive Reference 
2009 Mopti Patients with fever 150 B. melitensis: 58 Dao et al* 
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B. abortus: 49 
2006 Bamako Febrile patients  7.7 Steinmann et 
al** 
*: Dao et al. Seroprevalence of human brucellosis in Mopti, Mali, 2009. 
http://www.infectiologie.org.tn/pdf/revues/rti11/article_original2.pdf 
** Referenced in Akuku, 2013 [36]. 
 
Mozambique 
Animals:     
Year Area Species of animal No. of samples 
tested 








(RBT), 27.42 (ELISA) 
Tanner et al [47] 
2010 Maputo 
province 




Sheep & goats: 0 
Manhica et al* 






Year Area Species of animal No. of samples 
tested 
% positive Reference 
2015 Kigali Cattle 2017 RBT: 2.03 
c-ELISA: 1.7 
Manishimwe et al 
[48] 
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answer to OIE 
questionnaire 
Cattle  1.7 Akakpo et al [43] 




Year Area Remarks No. of samples 
tested 
% positive Reference 
2011 Huye Abattoir workers 68 14.7 Vivaldi* 
2006 Huye  Women with abortion/ 
stillbirth 
60 25 Rujeni et al [49] 
* Referenced in Akuku, 2013 [36]. 
 
Senegal 
Animals:     
Year Area Species of animal No. of samples 
tested 
% positive Reference 
2012 Dakar Dairy 300 25 Tialla et al, 2014 
[50] 
2009 Country 
answer to OIE 
questionnaire 





Gobra zebus 132 1.5 Kouamo et al* 
2003 Bassin 
Arachidier 
Cattle 479 animals, 30 
farms 
Individual: 0.6 
Herd level: 10 
Unger et al [51] 
* Referenced in Akuku, 2013 [36]. 
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Humans: No recent published information has been found.  
 
South Africa 
Animals:     
Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 





Gauteng Samples tested 
by OVI 










KwaZulu Natal Cattle 46025 1.45 Hesterberg et al** 
*Source: http://www.nicd.ac.za/assets/files/NICD-NHLS%20Communique%20January%202011.pdf  
**Referenced in Akuku, 2013 [36]. 
 
Figure 5, represents the number of brucellosis outbreaks in South Africa 2009-2014, and the location of the most 
recent outbreaks 2010-2014, as presented by Dr Mbizeni from the Disease Control Directorate. He mentioned 
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Figure 5: Recent brucellosis outbreaks in South Africa. Source: Brucellosis in South Africa: Progress and 
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Animals:     
Year Area Species of animal No. of samples 
tested 
% positive Reference 










Assenga et al [53] 




answer to OIE 
questionnaire 
Cattle  5.8 Akakpo et al [43] 
2007  Cattle and wildlife 2738 livestock 
90 wildlife 
Cattle: 6.2 
Small rum: 6.5 
Wildlife: 13 
Shirima** 


















Tanga Cattle: abattoir survey 51 12 Swai & 
Schoonman, 2012 
[56] 
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2003 Moshi (North) Cattle 417 Individual: 12.2 
Herd level: 41.9 
Swai et al, 2005** 
1995-
1997 
Dar es Salaam 
(Dairy) 
Lugoba (Zebu) 





Weinhaupl et al [57] 
1999 Iringa and 
Tanga 






*: Source: Beritlla Elias Lyimo. Prevalence of bovine brucellosis in smallholder dairy farms in Morogoro, 
Tanzania. MSc Thesis: 
http://suaire.suanet.ac.tz:8080/xmlui/bitstream/handle/123456789/585/BERTILLA%20ELIAS%20LYIMO.pdf?s
equence=1&isAllowed=y 
**Source: Akuku, 2013 [36].  
 
Humans:  
Year Area Remarks No. of samples 
tested 
% positive Reference 
2015 Katavi-Rukwa  340 1.5 Assenga et al [53] 
2013 Kilosa 
(Morogoro) 
Febrile children at Kilosa 
district hospital 
370 B. abortus: 7 
B. melitensis: 
15.4 
Chipwaza et al [58] 
2007-
2008 
Moshi Febrile admissions to 2 
hospitals 
453 3.5 Crump et al [59] 
2004 Tanga Volunteers various 
occupations 
199 5.52 Swai & Schoonman 
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Animals:     
Year Area Species of 
animal 
No. of samples 
tested 
% positive Reference 







Bovine milk: 29 
Goats: 17 







925 Individual: 8.64 
Herd level: 28.7 









2013 Luwero and 
Nakasongola 




2012 Kampala area Cattle 214 Individual: 3 




Gulu and Soroti Cattle Gulu: 500 
Soroti: 507 
Individual: 7.5 
(Gulu: 6, Soroti: 9.1) 
Herd level: 27.1 
(Gulu: 19, Soroti: 46) 
Mugizi et al [62] 
2011 Peri-urban Dairy cattle 423 Individual: 5 
Herd level: 6.5 
Makita et al. 
2011 [63]  
2011 Mubende Cattle and 
goats 
 Cattle: 11 individual, 
38 herd level 
Goats: 36 individual, 58 
herd level. 
Karimu Grace et 
al [64] 
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2010 Kampala Informal 
marketed milk 





and Tororo labs 





Kiboga, Mpigi and 
Kiruhura (West) 
and Kumi and 
Mbale (East) 
Cattle  Mpigi:  
2008: 5.3,   2009: 30 
Kiruhura: 
2007:8.1, 2009: 16.8 
Kumi: 









2009 Dairy and Pastoral Cattle Dairy: 226 
Pastoral: 497 
Dairy: 3.3 
Pastoral: 34  
Magona et al ** 
2006 Kampala Marketed milk 
samples 
162 44.4 Smith, 2006 
2006 Kashongi Cattle 258 10.2 Mugizi*** 
2005 Pastoral Cattle 10529 15.8 Faye et al** 
2004 Peri urban Cattle 245 42 Mwiine** 
2002 Mbarara Dairy cattle 315 herds Individual: 15.8 
Herd level: 55.6 
Bernard et 
al*** 
1998 Eastern and 
Western Uganda 
Goats 1518 Individual: 4 
Herd level: 43 
Kabagambe et 
al [67] 
Brucellosis | Monograph 21 






















*Source:  Pubmed abstract, ahead of printing: http://www.ncbi.nlm.nih.gov/pubmed/25660343 
**Source: As referenced in Boukary, 2014 [3].  
***Source: As referenced in Akuku, 2013 [36].  
****Source: Ellen Jonsson, 2013. Seroprevalence and risk factors for bovine brucellosis, salmonellosis and 
bovine viral diarrhea in urban and peri-urban areas of Kampala, Uganda. Veterinary Bachelors Thesis.  
Spatial distribution of Brucella antibodies among indigenous cattle in Uganda 2011- 2012. Source: Kabi et al [60] 
 
Mwebe conducted a review of the brucellosis diagnostics between 1998 and 2008. A total of 17,359 samples 
were analysed serologically, of which 1,061, 15,758 and 585 samples were from Makerere, Entebbe and Tororo 
laboratories, respectively. The overall seroprevalence of brucellosis was 10% while from individual laboratories 
was 38%, 32% and 7% for Makerere, Entebbe and Tororo laboratories, respectively.  Some of the data is shown 
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Figure 6: The spatial distribution of Brucella antibodies among indigenous cattle population in Uganda. 




Figure 7: Brucellosis seroprevalence in livestock in Uganda from 1998 to 2008: a retrospective study. 
Source: Mwebe et al [66]. 
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Year Area Remarks No. of samples 
tested 
% positive Reference 
2015 South West  236 11 Miller et al (ahead of 
publication)* 
2015 Kiboga Patients attending 
hospital 






patient with fever 
513 B. abortus: 21.8 
B. melitensis: 14 
Nabukenya et al [69] 
2011 Mubende Hospital records  31 Karimu Grace et al 
[64] 
2007 Kampala and 
Mbarara 




Nabukenya et al [70] 
Incidence: The annual incidence rate was estimated to be 5.8 (90% CI: 5.3–6.2) per 10,000 people by Makita et al 
[65] 
*Source:  Pubmed abstract, ahead of printing: http://www.ncbi.nlm.nih.gov/pubmed/25660343 
 
Zambia 
Animals:     
Year Area Species of animal No. of samples 
tested 








Chimana et al 
[71] 
2009 Wetlands Antelopes 44 42.9 Muma et al, 
2011[72] 
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answer to OIE 
questionnaire 
Cattle  Cattle: 2.5 
Sheep/goats: 4.7 
Akakpo et al [43] 
2008 Southern 
Province 
Cattle 395 20.7 Muma et al, 
2013 [73] 
2008 Southern and 
Lusaka 
Cattle 1323 6 Muma et al 
2012 [74] 
2007 Kafue flats Cattle 886 Individual: 23.9 
Herd level: 50 
Muma et al 
2007 [75] 
2006 Lochinvar and 
Blue Lagoon 
National Park 
Cattle, sheep and goats Cattle: 1245 




Herd level: 46.2-74 
Sheep and goats: 0 
Muma et al, 
2006 [76] 
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Economic and Social Impacts at Global 







The economic and social impact of brucellosis is due to the human, livestock and wildlife disease.  The economic 
and social impact vary by geography, livestock species, management system and capacity of the country’s 




Figure 8: Brucellosis disease impact. Source: Cost-benefit analysis of brucellosis control. Presented by 
Mieghan Bruce and Jonathan Rushton at the Sub regional meeting on brucellosis control Skopje, TFYR 
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Cattle: Losses are caused by abortion and later permanently reduced fertility and chronically lowered milk yields 
in affected animals (10-15% reduction).  In previously unexposed and unvaccinated cattle, B. abortus spreads 
rapidly and abortion storms are common. The abortion rate varies from 30% to 80%. In herds where this 
organism has become endemic, only sporadic symptoms occur and cows may abort their first pregnancies. 
McDermott (2002) estimated that seropositive cattle were 4.6 times more likely to abort. In a study conducted 
by McDermott in South Sudan, he found that positive cows had approximately 10% less calves. Abortions are 
less common in water buffalo cows than cattle. Deaths are rare in adult animals of most species.  
Small ruminants: The relative importance of B. melitensis for sheep and goats varies with the geographic region, 
and can be influenced by husbandry practices and the susceptibility of sheep breeds in the region. Management 
practices and environmental conditions significantly influence the spread of infection. Lambing or kidding in 
dark, crowded enclosures favours the spread of the organism, while open air parturition in a dry environment 
results in decreased transmission. The abortion rate is high when B. melitensis enters a previously unexposed 
and unvaccinated flock or herd, but much lower in flocks where this disease is enzootic. The animals usually 
abort only during the gestation when they are first infected. Inflammatory changes in infected mammary glands 
usually reduce milk yield by a minimum of 10%, but there are reports of up to 28% in goats (Alton 1985). Fertility 
in males can be permanently impaired. Deaths are rare. 
Pigs: In domesticated pigs, the abortion rate from B. suis varies widely, from 0% to 80%. 
 
Good analysis of the economics of brucellosis impact and control in low-income countries has been published by 
Mc Dermot in 2013 [1] and includes an extensive literature review. Some of the data reviewed on the impact of 
brucellosis mentioned includes: 
• Studies on the economic production loses of bovine brucellosis are reasonably consistent across a range 
of production systems in Africa, with losses estimated at 6% to 10% of the income per animal.  
• At the end of the last century, economic losses for Argentina were estimated at US$60 million per year 
or US 1.20 per bovine when the prevalence was around 5%. 
• In Nigeria losses were estimated at US 575,605 per year or US3.16 per bovine with a prevalence 7-12%.  
• Productivity losses from B. melitensis are less documented. One study in India estimated the annual 
economic loss at Rs 1180 (US$21) and Rs 2121.82 (US$ 38) per infected sheep and goat respectively. B 
melitensis usually occurs in outbreaks rather than in a more regular endemic pattern.  
• Brucellosis in pigs has productivity and economic impacts but there is little information on their 
magnitude in low income countries.  
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If a country has a control program, a cost-benefit analysis of the program can be done, using local data if 
possible. Some points to consider are the extra costs of brucellosis (the basic costs of the new control program, 
and increased livestock numbers) and the Revenue foregone (if there is test and slaughter policy, it would 
include the lost revenue from a culled dairy cow, and unintentional consequences, e.g. abortion due to 
vaccination of a pregnant animal). Benefits include the costs saved (for not implementing control efforts and 
from reduced human cases) and extra revenue from an improved livestock productivity from losses avoided due 
to a reduced prevalence, and lost income avoided by reducing number of sick people (based in presentation by 
J. Rushton, Skojpe 2014).  The private and public costs to be evaluated when considering or evaluating control 




Figure 9: Costs to be considered and estimated in planning brucellosis control and eradication programs. 
Source: McDermott, 2013 [1]. 
 
Analysis by the World Bank: 
The World Livestock Disease Atlas – a quantitative analysis of global animal health data [77], published by the 
World Bank (with cooperation of OIE and FAO) in 2011 is an attempt to understand which livestock diseases 
cause the heaviest losses, which countries suffers the worst disease-related losses and which livestock species 
are most affected.  http://www-
wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2012/02/17/000356161_2012021703084
1/Rendered/PDF/668590WP00PUBL00Livestock0Atlas0web.pdf 
The World Livestock Disease Atlas bases its analysis on the Livestock Units (LSU).  Each species has a LSU value, 
and the losses of LSU have been given a value.  See Figure 10. For more information on the methodology 
description, please refer to the World Bank Atlas itself (pages 6 & 7). Brucellosis is one of the top 10 diseases 
causing losses for cattle, buffalos and small ruminants, as shown in Figure 11. However, looking at the data in 
detail, there are few data from sub-Saharan Africa and Asia.  
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Figure 11: Top 10 diseases in terms of LSU losses for cattle, buffalo, and sheep & goats. Source: World 
Livestock Disease Atlas – The World Bank, 2011 [77]. 
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Worldwide millions of humans are at risk, especially in developing countries where the infection in animals has 
not been brought under control, heat treatment procedures of milk are not routinely applied, and food habits 
such as the consumption of raw milk and poor hygienic conditions favour human infection. Brucellosis is also an 
occupational disease; most cases tend to occur in abattoir workers, veterinarians, hunters, farmers, and 
livestock keepers. People who do not work with animals usually become infected by ingesting unpasteurized 
dairy products. Brucellosis is also one of the most easily acquired laboratory infections. In humans, brucellosis 
usually produces a grave and debilitating disease that may become chronic and requires prolonged treatment. 
Complications are seen occasionally, particularly in the undulant and chronic forms. The most common 
complications are arthritis, spondylitis, epididymo-orchitis and chronic fatigue. Neurological signs occur in up to 
5% of cases. Brucellosis is rarely fatal if treated; in untreated persons, the case fatality rate vary from less than 
2% to 5%. Deaths are usually caused by endocarditis or meningitis. The incidence and severity of disease varies 
with the species of Brucella. B. melitensis is considered to be the most severe human pathogen in the genus 
Brucellosis affects approximately 500,000 people annually worldwide [78]. The disease is severely under-reported 
in humans, and acute febrile illness are often mistaken for malaria or other febrile diseases – an example in 
Tanzania showed that of 870 febrile patients, 60% were clinically diagnosed with  malaria, but it was the actual 
cause in only 1.6% [59]. The reported incidence ranges from less than 0.01 to more than 200 cases per 100,000 
population [2]. 
A recent systematic review on the burden of brucellosis [80], concluded that the incidence varied significantly 
within regions and within countries and aggregated data do not capture the complexities of disease dynamics 
and at-risk populations may be overlooked. Also as many brucellosis endemic countries do not have strong 
health systems, passively acquired data likely underestimates the true burden.  
Disability adjusted life years (DALY’s): The WHO Estimates of the global burden of foodborne diseases Report, 
published in December 2015, 
(http://www.who.int/foodsafety/publications/foodborne_disease/fergreport/en/), estimates the Disability 
adjusted life years (DALYs) due to Brucella spp is 264,073 and 2 DALYs per 100,000 persons.  See Figure 12 and 
Table 2. 
 
 Median number of DALYs Median DALYs per 100,000 persons 
Brucella spp 264,073 2 
E. granulosus 183,573 0.6 
M. tuberculosis 607,775 9 
T. solium 2,788,426 41 
 
Figure 12: WHO estimates of the global burden of foodborne diseases of interest for IDRC.  
Data source: WHO estimates of the global burden of foodborne diseases: foodborne burden epidemiology 
reference group 2007-2015 
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DALYs have been previously calculated for specific countries like Mongolia, where it was used to model the 
benefit of a brucellosis control program, which would have a cost of US$ 19 per DALY averted [79] (as a rule of 
thumb, interventions that cost less than US$ 150 per DALY averted are “attractive”, and less than US$25 are 




Figure 13: Scatterplot of the global burden of foodborne diseases per 100,000 population and per incidence 
case Source: WHO Estimates of the global burden of foodborne diseases, 2015. (Note: axes use log scales).  
The red arrow points at Brucella spp. Green arrows point at other diseases of interest for IDRC (T. solium, 
Mycobacterium bovis and E. granulosus) 
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Impact on specific focus countries: 
There are no published reports about the specific economic or social impact of brucellosis in the countries of 
interest.   Specific country evaluations, usually refer to the assessment of benefit-cost ratio of brucellosis control 
programs, as for example has been done in Nigeria and Mongolia [1], and more recently in Kirghizstan.  Different 





Figure 14: Different types of benefits and costs of animal brucellosis mass vaccination in Mongolia (Source: 
Bassirou Bonfoh, Economics of brucellosis, presentation at the workshop on integrated approach to 
controlling brucellosis in Africa, Addis Ababa, 2013) 
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Livestock suffering from brucellosis are generally not treated. Brucella spp may undergo L-transformation when 
exposed to certain antibiotics, resulting in a cell wall deficient form [81].  The effect in preventing serological 
detection and resultant creation of carrier animals is not clear.  
However, it has been demonstrated that long and complex treatments can successfully eliminate shedding of 
organisms from long-term carriers in cattle [82] and small ruminants [83], but it is believed to be economically 
unviable.  For example the most practical, effective and least expensive regimen for sheep and goats required 
long acting oxytetracycline 25 mg/kg IM every 2 days for 4 weeks, combined with streptomycin 20 mg/kg IM 
every 2 days for 2 weeks. 
No treatment has proved effective and economically feasible in treating pigs. In general, antibiotic therapy in 
pigs has been effective in limiting the bacteremic stage of the disease, but after therapy was discontinued, viable 
B. suis were still present in tissues. In carefully selected circumstances it would probably be possible to suppress 
multiplication of B. suis in vivo sufficiently to alleviate clinical signs and shedding.  
Recent developments:  Dr Steven Olsen (USDA) has been doing trials to evaluate the new macrolids against B. 
melitensis in sheep. Preliminary results indicate that they are not effective during the abortion stage; they did 
not prevent abortion (presumed the foetus were already colonised at the time of treatment) but further analysis 




Biosecurity measures to ensure the disease does not enter the herd are useful but might be very difficult to 
implement in the settings that characterise the developing world. New animals entering the herd, as well as 
semen, should come from Brucella negative herds/farms.  Animals entering the herd should be quarantined and 
tested, before they are allowed to mix with the remaining animals.  
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Vaccination is a very effective way of prophylaxis.  The different types of vaccines, their advantages and 
disadvantages, are discussed in Section 6.  Livestock vaccines currently available are effective in reducing 
production losses and reducing transmission, but do not prevent the animals getting infected, or seroconverting 
after exposure to virulent strains.  
 
Options and strategies for control programs at national, sub-national or regional level:  
Control of brucellosis is a long term program that should be adapted to the local circumstances. The most 
successful efforts to control and in many cases eradicate brucellosis have been in high and middle income 
countries (and one low income country, Nigeria).  The general pattern has been to establish a diagnostic and 
surveillance system and estimate the prevalence and distribution of brucellosis.  Based on the prevalence 
results, different strategies might be applied (see Figure 15 below).  Initial control measures, including 
vaccination, may be implemented to reduce an initial high prevalence.  From there, testing, quarantine and 
slaughter with compensation policies are established. Sometimes special measures are required in late stages 
for high risk populations.  Often, the final stages are the most difficult, when prevalence rates are low and the 




Figure 15: Decision Tree for brucellosis control as recommended by FAO (Source: Strategies and options for 
control and surveillance of brucellosis by Ahmed ElIdrissi. Presented at the Sub regional meeting on 
brucellosis control Skopje, TFYR Macedonia, Nov 2014).  
http://www.fao.org/fileadmin/user_upload/Europe/documents/Events_2014/Bruc_skopje/Brucellosis_strategies_Skopje
.pdf)   
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When implementing test and slaughter, there are important points to consider: where do replacement animals 
come from? Are there enough funds to compensate farmers? Are animals individually identified to ensure 
seropositive animals are correctly identified? It is socially and culturally acceptable? (e.g. culling cows in Hindu 
areas).  
Attempts to control and eradicate brucellosis in middle-income countries using the classical approaches have 
been much less successful.  These include the attempts in Mongolia which progressed at a very slow pace, as 
well as less than successful control programs in Egypt, Israel (B. melitensis), Macedonia, India and the Azores.  In 
low and middle income countries, more targeted control measures may be more realistic. Under conditions of 
high to moderate prevalence, inadequate veterinary resources, inability to control livestock movement, 
widespread brucellosis in feral animals or wildlife, livestock owners unaware of the importance of the 
programme or not strongly committed to public disease control, or limited diagnostic capabilities, targeted mass 
vaccination of all animals (including adults) might be the optimal tool for reducing level of infection. Reduction 
of prevalence through targeted and time-bound vaccination campaigns may be economically beneficial as it 
could stop the spread of an outbreak of B. melitensis.  Such approach has been reported to be successful in 
Tunisia and Morocco [1]. The strategy chosen will depend of the country resources, the epidemiological situation, 
the political will, the legal framework (for example legislation required for test, slaughter and compensation), 
veterinary services and laboratory infrastructure, animal movement control, animal/herd identification practices 
and availability of good quality vaccines. 
 
AU-IBAR has developed Standard Methods and Procedures (SMPs) for control of Brucellosis in the Greater Horn 
of Africa [84].  In the considerations for vaccination, it is stated that an effective vaccination requires coverage of 
over 80% of the eligible animal population, and vaccination carried out for a period greater than twice the 
average production life (over 10 years in sheep and goats). They suggest that in the context of the region, it may 
be possible to combine vaccination campaigns for brucellosis with those being implemented for other diseases 
like PPR or CBPP.  
 
As for considerations of the different scenarios in the Greater Horn of Africa, they define high-prevalence, 
endemic situation in small ruminants, when there is over 5% herd prevalence and in those cases mass 
vaccination is recommended. Where risk factors cannot be controlled (for example, under conditions of 
transhumance), vaccination is recommended even when the prevalence is lower.  
 
Advantages and disadvantages of the different brucellosis control strategies, can be seen in Table 3 below. 
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Table 3: Advantages and disadvantages of Brucellosis control strategies: 
Source: Brucellosis in Sheep and Goats. European Commission. Scientific Committee on Animal Health and 
Animal Welfare.SANCO.C.2/AH/R23/2001 
 
Strategy Advantages Disadvantages 
Mass vaccination 1. Reduces zoonotic impact 
2. Herd immunity quickly established 
3. Effective disease control and reduction in 
losses due to disease 
4. Well accepted by owners 
5. Easy to manage and economical 
6. Flock immunity can be maintained by 
vaccinating young animals 
1. Vaccine induced abortions in 
pregnant animals 
2. Distinguishing infected form 
vaccinated animals is not feasible in 
the short term 
3. Infected animals remain on farm for 
some time 
Vaccination of young 
animals and test and 
slaughter of older 
infected animals 
1. Minimises vaccine induced abortions 
2. Serological response reduced in vaccinated 
non-infected animals allowing test to 
differentiate infected and vaccinated 
animals 
1. Herd immunity slowly established 
(unless moving from mass vaccination 
strategy) 
2. Serological test to differentiate 
infected and vaccinated animals are 
not optimal and cannot be relied 
upon for accurate diagnosis of an 
individual animal 
No vaccination 
Test and slaughter 
1. If successful will result in elimination of the 
infection in the region 
2. Diagnostic test are more accurate in non-
vaccinated animals but still not optimum 
1. Risk of epidemics and subsequent 
human infection 
2. Higher cost 
3. Need efficient veterinary services 
(animal identification, laboratory 
support, movement control) 
4. Suitable for low disease prevalence 
areas only  
5. Removal of protective cover of 
vaccination may allow disease 
prevalence to increase 
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Disease situation and government policies by country 
Tables 4 and 5 below have been partially completed with information from Akakpo, Teko-Agbo and Kone 
presented at an OIE conference in 2009 [43], and updated with data published by Akuku [36], data obtained by the 
consultant earlier in the year, and data from a brucellosis workshop conducted by the Brucellosis ZELS project in 
Dakar in June 2015 (data not published, but kindly shared by Dr Javier Guitian).  It also includes information from 
the questionnaires sent to the DG and DVS offices of the different countries. 
  
Table 4 covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or control 
programs, and the treatment situation.  Table 5 refers to vaccination. 
 
The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination 
of information to those who need to know so that action can be taken.  
2Control: a programme which is approved, and managed or supervised by the Veterinary Authority of a country 
for the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that 
country, or within a zone or compartment of that country. 
 
Table 4: Official status, official programs and treatment for Brucellosis in the countries of interest.  



















Bangladesh # Ba: Yes 
Bm: No 
Bs: N/A 
No No No - 
India      
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Indonesia      
Myanmar # 
(Burma) 
Yes Ba, Bm: Yes, passive 
Bs: No 
No No Yes 
Nepal # Yes Yes, passive No No No 
Vietnam # No No No No Yes 
AFRICA 
Burkina Faso & Yes Yes* Yes No No 
Côte d'Ivoire # 
(Ivory Coast) 
Yes  Yes, Passive Yes No  
Ethiopia *  No    
Kenya # Yes Yes, active/passive # 
No** 
No No # 
Yes & 
No 
Madagascar      





Mali # - # 
Yes & 
Ba: yes, passive 
Bm, Bs: - 
Ba: Yes # 
Bm, Bs: N/A # 
No*** 
No No 
Mozambique &    No Yes 
Rwanda %. # Yes Yes*** Yes*** No # No # 
Senegal & Yes  Yes   
South Africa      
Tanzania # Yes Yes, passive # No No No 
Uganda # No No # 
Yes, passive* 
No No Yes (only 
supportive) 
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Zambia # & Yes Ba, Bm: Yes, active 
Bs: No 
Ba, Bm: Yes 
Bs: No 
No  No # 
Yes & 
 
Countries mark indicates the main source. If different answers have been found, they are marked within each box.  
#  Data from the questionnaire submitted as part of this monograph to the DG/DVS offices. 
&: Data from Akakpo 2009 
* Data from communications between the consultant and various country representatives in May 2015.   
** Source: Data from Akuku, 2013 
*** Source: Data from Craighead et al. “Brucellosis in West and Central Africa: Situation Analysis (ZELS project report 
submitted for publication) kindly provided by Dr Javier Guitian. 
% During the workshop conducted in June 2015, and described in Craighead et al. “Brucellosis in West and Central Africa: 
Situation Analysis (ZELS project report submitted for publication), the participant from Rwanda reported the existence of 
a national brucellosis surveillance and control programme. Surveillance activities are carried out in abattoir and in live 
animals, as well as vaccination of young female cattle using RB51.  Further testing is carried out on animals produced for 
the ‘One family, one cow’ programme where any positive animals are culled. Through this system positive small ruminants 
have also been identified. 
 
Table 5: Vaccination for Brucellosis in the countries of interest.  











Who delivers the 
vaccine (official, 
private vaccinators or 
both) 
Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
ASIA 
Bangladesh # No - - - 
India     
Indonesia     
Myanmar # (Burma) No Ba: Farmers 
Bm, Bs: - 
Ba: Private 
Bm, Bs: - 
Ba: Cattle 
Bm: sheep/goat 
Nepal # No N/A N/A N/A 
Vietnam # No Farmers Private vaccinators Ba, Bm: cattle 
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Burkina Faso & Not authorised - - - 
Côte d'Ivoire (Ivory 
Coast) # 
No Farmer Private vaccinators Cattle 
Ethiopia     
Kenya # No Farmer Both Cattle, sheep, goats 
Madagascar     
Malawi &, # Not authorised - - - 
Mali & Not authorised - - - 
Mozambique     
Rwanda # No Government Official Cattle 
Senegal     
South Africa     
Tanzania # No Ba: Farmers 
Bm, Bs: Not done 
Ba: private 
vaccinators 
Bm, Bs: Not done 
Ba: cattle 
Uganda # No Ba, Bm: Combination 
(but mainly farmers) 





Zambia # No Ba, Bm: Farmer Ba, Bm: Both Ba, Bm: cattle 
 
Countries mark indicates the main source. If different answers have been found, they are marked within each box.  
#  Data from the questionnaire submitted as part of this monograph to the DG/DVS offices. 
&: Data from Akakpo 2009 
-: Questionnaires received, but no information provided.  
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There are several different types of vaccines for brucellosis. Tables 6 and 7, show a summary of the 
characteristics of the main vaccines for B. abortus, B. melitensis and B. suis, based on the information from the 
OIE Terrestrial Manual, Discontools, and the most recent publications on brucellosis vaccines reviews, including 
publications from Dorneles in 2015 [85], Avila-Calderon [86], Yang [87] and Olsen [88] in 2013, and Siadat in 2012 [89]. 
It also includes specific reviews for vaccines from Russia [90] and China [91].  
 
B. abortus 
There are 2 vaccines recognized by the OIE for B. abortus in cattle: the Strain 19 (S19) is the reference vaccine, 
and the RB51. Both are live vaccines and are widely used.  There used to be an inactivated vaccine, the 45/20, 
but it has been discontinued. In South Africa, OBP produces S19 low dose (1 to 10 X 108 cfu/dose). This low dose 
vaccine triggers CFT antibodies for a limited period which can be used to monitor seroconversion, but the 
animals remain negative to c-ELISA. This low dose vaccine has been used during outbreaks to provide good 
immunity also in adult animals while preventing a strong serological response. See Table 6.   
In Russia over 50 vaccine strains have been evaluated [90], and 5 have been incorporated into veterinary practice 
(S19, 104-M, 82, 75/79-AB and KB17/100).  The SR-B. abortus strain 82, is the most commonly used, and it is 
commercially available manufactured by Shchelkovo Biocombinat (http://biocombinat.ru/en/catalog/32/425/). 
It was approved for use in 1974, but can cause abortions in pregnant cattle. The other vaccine widely used since 
1997, is the strain 75/79-AB (which seems to be a dissociated form of strain 82) and is also manufactured by 
Shchelkovo Biocombinat (http://biocombinat.ru/en/catalog/32/424/). Both have weak agglutinogenic 
properties, and provide good immunity. The main advantage of 75/79AB is that it does not seem to produce 
abortions in cattle.  
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Some patents for B. abortus vaccines have been more widely publicised: 
1. In 2009, it was announced that Drs Delvecchio, R.A. Ugalde, J.E. Ugalde and D.J. Comerci, were awarded 
United States patent # 7,541,447 B2, for a live attenuated vaccine that prevents brucellosis.  The brucellosis 
Delta-pgm vaccine is a live attenuated and genetically defined mutant with a deleted portion of the 
phosphoglucomutase gene. This deletion mutation results in a substantially less virulent organism which has 
retained its protective ability as a vaccine. Since it is a deletion it also has no capability to revert to a virulent 
organism. A master seed lot of the vaccine has been produced and used in several cattle studies. Standard 
production methods using bacterial fermentation are used to produce the Delta-pgm vaccine. The vaccine 
does not interfere with diagnostic methods for brucellosis and it induces a higher degree of protection in 
comparison with S-19 strain. Dr. Delvecchio is President and founder of Vital Probes, Inc. a biotechnology 
firm in Pennsylvania that is seeking investors to commercialise the vaccine. According to their website, 
Licensure of the vaccine is available on a per country or a global scale.  They have been contacted to find the 





2. In August 2013, the patent of a Brucella abortus S19 vaccine expressing green fluorescent protein (S19-GFP) 
was announced by the National University (UNA), University of Costa Rica (UCR) and the Public University of 
Navarra (Spain) This recombinant vaccine would allow the differentiation between vaccinated and naturally 
infected animals. An accompanying ELISA has also been developed and patented. It would seems this 






There is only one vaccine recognized by the OIE for use in sheep and goats for B. melitensis, the Rev1. In China, 
the M5 (or M5-90) vaccine, derived from strain M28 was developed in Harbin, and has been used widely in goats 
and sheep since 1970 (91, 92). It is commercially produced by the China Animal Husbandry Group. According to 
the publications (91,92), M5-90 can be used in pregnant animals, however the commercial manufacturer 
recommends not to use in pregnant animals.  Some information was obtained from the following link: 
http://baike.baidu.com/view/2532416.htm. It seems that the vaccine can also be given as an indoor or outdoor 
aerosol, but that route would create concerns for human safety, and transmission to all animal including 
Brucellosis | Monograph 21 






lactating ones, that would transmit the Brucella in milk.  The manufacturers of M5-90 say that the vaccine is 
pathogenic for humans, so they need to use protection during aerosol vaccination, but no further guidance is 
given (information provided by Ms Shumin Li).  The manufacturers of M5 also say that the vaccine can be used in 
cattle, but it is not clear if it is for protection against B. abortus, B. melitensis or both. See Table 7. 
B. melitensis vaccines for cattle: According to the OIE Terrestrial Manual, it is not infrequent to isolate B. 
melitensis in cattle in countries with a high prevalence of this infection in small ruminants. There has been some 
debate on the protective efficacy of S19 against B. melitensis infection in cattle and it has been hypothesised 
that Rev.1 should be a more effective vaccine in these conditions. However, there is very little information 
related to this issue. Evidence proving that S19 is able to control B. melitensis at the field level is also scanty. No 
experiments have been reported showing the efficacy of Rev.1 against B. melitensis infection in cattle. 
Moreover, the safety of this vaccine is practically unknown in cattle. Until the safety of Rev.1 in cattle of 
different physiological status and efficacy studies against B. melitensis under strictly controlled conditions are 
performed, this vaccine should not be recommended for cattle. 
 
Brucella suis 
The only commercial pig vaccine for the prevention of B. suis is produced in China (http://www.cahic.com/).  
http://www.cahic.com/pham/index.php?optionid=357&auto_id=570. The manufacturers were contacted via 
the web to obtain additional information, but not reply was obtained. Research conducted by Ms Shumin Li, 
clarified that the manufacturers claim that the vaccine can be used orally in pregnant animals, but no IM.  The 
manufacturers also claim duration of immunity for cattle, sheep and goats, but it is not clear for which type of 
Brucella.  As for interference with serology, it would seem that even if it is a smooth strain, the interference with 
diagnostic tests is not long term. See Table 7.   
http://www.ncbi.nlm.nih.gov/pubmed/3541425 
A promising experimental vaccine, is strain 353-1. It is a natural rough mutant that does not induce immune 
responses as detected on the traditional diagnostic tests, is not shed after vaccination, and is clinically safe in 
pigs [93].  Dr Steve Olsen who is leading the USDA team involved in the development of this vaccine, has provided 
further information (please see Section 7, note 1, page 48) 
 
Human vaccines 
China is one of the few countries to have a vaccine for humans, the strain M-104 vaccine, which has also been 
used in Russia. It is a B. abortus isolated from the foetus of an aborted calf in 1950 by a Russian scientist; tests 
indicated the M strain had low virulence, stability and high immuno-antigenicity. The scratch vaccination was 
used in China to introduce five billion bacteria and achieved 90% of protection and 12 month duration. The 
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vaccine has been adopted for use in humans since 1965. However, the epidemiology of the human brucellosis 
situation in China become more severe during 2005-2010 [94].   




Strain 19 RB51 45/20 Strain 82
Status In use. Recognized by OIE 
(Reference vaccine).
In use. Recognized by OIE. Used, but stopped In use: Russian Federation, 
Azerbaijan, Tajikistan and 
others
Type Live: B. abortus  biovar 1
(Smooth)
Live: B. abortus  biovar 1
(Rough)
Killed: B. abortus  biovar 1 
(Rough)
Live: B.abortus  biovar 6
Origen Naturally attenuated by room 
temperature for 1 year
Subculture on medium with 
rifampicin and penicillin
Isolated after 20 passages in 
guinea pigs.
Selecting colonies from an 
aborted bovine foetus. 
Target species Cattle Cattle Cattle and sheep Cattle
Other species Water buffalo Safe in water buffalo (but 
does not protect natural 





B. melitensis : Debatable that it 
is protective against B. 
melitensis  in cattle (OIE), 
DISCONTOOLS says it is 
effective.  It is protective 
against B. melitensis  in sheep, 
but Rev1 is better. 
B. suis :  ?
B. ovis :  ?
B. melitensis : No
B. suis : No
B. ovis : No
Indications Female calves 3-6 months of 
age
Calves Heifers 3-6 months.
Immunity Lasting immunity to moderate 
challenge, but precise duration 
is unknown.
Long immunity to moderate 
challenge, but duration 
unknown. In risk areas, 
revaccinate after 12 months of 
age. Booster suggested after 4-
5 years
Two consecutive 
vaccinations, 6-12 months 
apart.
Repeat in heifers after 10 
months. Immunity lasts 1 
year. 
Route Usually SC (or conjunctival) SC IM SC
Dose Calves SC: 5-8 x1010 viable 
organisms.  Adults SC: reduced 
dose 3 x108 - 3 x 109 but some 
side effects. Conjunctival any 
age: 5x109 viable organisms
Calves 4-12 months: SC: 1-3.4 
x1010 organisms. Reduced dose 
1x109 recommended for adults
Serology on 
standard tests
Positive (induces anti-LPS Ab). 
Prolonged high titres with 
booster vaccination
Negative (does not induce 
anti-LPS Ab), even on booster 
vaccination. No 
seroconversion in RBT and 
CFT, but detectable with 
ELISA.
Not completely free of the O-
chain, can induce Ab 
detectable by serology
Intermediate: it express 
some O Ag on its surface, 
but humoral response less 
robust and shorter. No 
response in agglutination 
tests
B. abortus
Brucellosis | Monograph 21 












Strain 19 RB51 45/20 Strain 82
Pathogenicity Moderate to high Low
Efficacy Highly effective in reducing 
production losses and disease 
transmission. Less efficacious 
at preventing infection (& 
seroconversion). Efficacy is 
challenge dose-dependant
Similar to S 19, but there is not 
generalized agreement. Never 
proven more effective than 
S19.





Significant human pathogen Reduced pathogenicity 
compared with S19, but still 
infections, and it is resistant 
to rifampicin, one of the most 
potent antibiotics used for 
Brucellosis
Use in pregnant 
animals
Low dose may cause significant 
abortions (3.2%) and high titres
Occasional abortions (less 
than 0.2%). Some claims are 
higher.




Significant reduction in milk 
production has been reported. 
Recovered 10% milk samples.  
Can't be used in males due to 
persistent orchitis.
Not safe in males. When used live, reverts to S 
pathogenic form when 
injected in cattle. 
First used 1923 Mid 1990's Russia: 1974
Large scale use Yes Yes Yes, in Russia
Others More expensive than S19 Was used in some EU 
countries to replace S19, but 
was stopped due to the be 
variability in protection and 
unpredictable serology.
Strain 75/79-AB (a 
dissociated form of strain 
82) seems not to induce 
abortions in cattle. 
B. abortus
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Rev 1 M5 or M5-90 H38 Strain 2 353-1
Status In use. Recognized by OIE 
(Reference vaccine).
In use: China Experimental. 
Abandoned
In use (China only) Experimental
Type Live
(Smooth)
Live: B. melitensis 
biovar 1




Origen Passage on streptomycin 
media. Resistant to 2.5u/mL 
streptomycin and susceptible 
5 IU penicillin G.
B. melitensis  virulent 
strain M28 passaged 
through chicken
Laboratory adopted, 
isolated from an 
aborted sow and 
attenuated by serial 
passage.
Target species Small ruminants Goats and sheep Mice and cows Pigs
Other species Little known about Rev1 
preventing melitensis in 
cattle. OIE does not 
recommend the use in cattle.




B. abortu s: One study showed 
to be more protective than 
S19 in cows, however there 
are also reports of virulence.
B. ovis : Yes
B. suis :
B. abortus : Yes
B. melitensis : Yes, but 
Rev1 is better. Others 
say no.
B. ovis : Contradictory 
information.
Indications Lambs 3-6 months
Immunity Solid and durable immunity, 
but declines with time. 
Revaccination advisable in 
endemic areas.
Three years Immunity declined 
compared to S19 and 
RB51.  Two-three years.
Robust humoral 
and cell-mediated
Route SC or conjunctival SC, intranasal, aerosol Oral (water) SC or orally
Dose 0,5-2 x109 CFU/dose Cattle SC: 25x109, 
indoor aerosol 
25x109, outdoor 
aerosol 40x109. Goats 
& sheep SC or IN: 
1x109, indoor aerosol: 
1x109, outdoor 
aerosol: 5x109, oral 
25x109.
10x109 bacteria 1010 CFU/dose
Serology on 
standard tests
SC: Positive Ab response.  
Used conjunctival to minimise 
response.
Yes. Cattle: up to 6 
months in 5-10% 
animals by cELISA, but 
usually less than 3 
months.  Goats and 
sheep: not detected 
by cELISA after 4 
Persistent Ab 
titres
Does not induce 
persistent Ab. Strange 
being smooth strain?




Pathogenicity Safe enough to be used in 
young rams or billy goats
Less than S19 and Rev1 
in mice
Efficacy Highly effective in reducing 
production losses and disease 
transmission. Less efficacious 
at preventing infection (& 
seroconversion).
Lack of sufficient 
protection after 
challenge
Highly effective in 
reducing production 
losses and disease 
transmission. Less 
efficacious at 
preventing infection (& 
seroconversion).
B. suisB. melitensis
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Commercial vaccines manufactured in Africa and Asia  
 
The information summarised in Tables 8 and 9 below, is based on information from The Center for Food Security 
and Public health, Iowa State University (www.cfsph.iastate.edu/vaccines/index.php and Vetvac 
(www.vetvac.org).   More details have not been gathered, as another consultant has been commissioned to 
perform this task.  
Table 8: Manufacturers of Brucella abortus vaccines in Africa and Asia. 
 




Veterinary Vaccine Research 
Institute 
Egypt Brucella abortus  
Strain 19 Vaccine 
Live Arab Rep, West Bank 
and Gaza 
NVRI Nigeria Brucella S19 Vaccine Live  
OBP South Africa Brucella S19  Live Namibia 
MSD Animal Health (Merck) South Africa RB-51® Live  
Rev 1 M5 or M5-90 H38 Strain 2 353-1
Zoonotic 
characteristics
Yes. More virulent than S19. Yes
Use in pregnant 
animals
Can induce abortions. It seems to be safe
Other side 
defects
Occasional excretion into the 
milk
First used 1957 China: 1970 China: 1980's
Large scale use Yes: Tajikistan, Portugal Yes: China Only China
Others It shows instability, so QC is 
essential. Subject to varying 
its morphological and 
immunological properties
B. suisB. melitensis
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Qilu Animal Health Products 
Factory 
China Brucellosis vaccine 
A19 
Live  
China Animal Husbandry Group China Bovine Brucellosis 
S19 (for pig & sheep) 
Live  
China Animal Husbandry Group China M5 or M5-90 (for cattle & 
sheep) 
Live  
Hester Biosciences Limited India Brucella abortus  
S19 
Live  
Indian Immunologicals Limited India Bruvax 
S19 
Cattle & buffalo 
Live  
Institute of Animal Health and 
Veterinary Biologicals 
India Brucella abortus S19 Live  
Pusvetma Indonesia Brucivet S19 Live  






Table 9: Manufacturers of Brucella melitensis vaccines in Africa and Asia. 
 




OBP South Africa Brucella Rev.1  Live Namibia 
Vaccine Research Institute Egypt Brucella melitensis Vaccine 
Rev1 
Live  
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Commercial vaccines imported into Africa and Asia 
 
The information summarised Table 10, is based on the same sources mentioned in Table 9, as well as a 
questionnaire sent to the Directors of Veterinary Services office and regulators of the countries of interest.  Note 
that some vaccines might have been imported under DVS dispensation, and they are not necessary licensed in 
the country.  
 

























Bangladesh - - - - - - - 
India        
Indonesia        
Myanmar 
(Burma) 
- - - - - - - 
Nepal - - - - - - - 
Vietnam - - - - - - - 
AFRICA 
Burkina Faso        
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Rev1 Jordan     
Kenya - - - - - - - 
Madagascar        
Malawi N/A N/A N/A N/A N/A N/A N/A 
Mali N/A N/A N/A N/A N/A N/A N/A 
Mozambique        
Rwanda - RB51 USA 10,000 5,000 2,000 - 
Senegal        
South Africa        
Tanzania  - - - - - - - 
Uganda - S19 Various 4,000 16,000 0 60,000 
Zambia 
 
- S19 South Africa 26,790 63,900 39,000 - 
- RB51 South Africa 6,250 6,000 1,600 - 
 
-   Questionnaire received, no information provided. 
 
Other comments 
JOVAC, the manufacturer from Jordan was also sent a questionnaire designed for key importers into the region.  
They confirmed that they export B. abortus S19 vaccine (Bruce19 vac) to Asia and Africa, and B. melitensis Rev1 
(Brucevac) also to Africa and Asia. They did not specify the countries or the volumes.  
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The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.   
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP showed in Table 11 below, should be considered a 
proposal, a live document subject to improvements.  
Information on current vaccines has been obtained from the datasheet of different products. An example of 




Rev1 ocular: http://www.czveterinaria.com/en/productos/ocurev.html  
 
Table 11: Target Product Profile (TPP) Brucella vaccine – Proposal: 
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen 
 
Immunogen with protective antigens 
for Brucella abortus OR B melitensis  
Immunogen with protective antigens to 
Brucella abortus, B. melitensis, B. ovis 
AND B. suis  
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2 Indication for use For active immunization of cattle OR 
sheep and goats.  
Some strains are not indicated for 
adult animals or males.   
For active immunization of cattle, water 
buffalo, sheep, goats and pigs of all ages 
and sexes.  
3 Recommended species 
 
Cattle or sheep and goats Cattle, buffalo, sheep, goats and pigs. 
Also all susceptible animals, including 
susceptible wildlife that may get in 
contact with domestic livestock. 
4 Recommended dose 
 
Cattle: 2 - 5 ml SC 
Sheep and goats: 1-2 ml SC 
Intraocular: 0.035 ml (one drop) 
Same dose for all species (2 ml) 




Ready to use solution/suspension 
6 Route of administration 
 
SC or conjunctival 
(B. melitensis M5 China: aerosol) 
SC, Intramuscular or conjunctival  
7 Regimen - primary 
vaccination 
Single dose Single lifetime dose 
8 Regimen - booster S19: No 
RB51: Single annual booster (if 
desired, but not required) 
Rev1: No 
Lifelong immunity after primary 
vaccination 
9 Epidemiological relevance Protection against B. abortus OR B. 
melitensis  
Protection against B. abortus, B. 
melitensis, B. ovis AND B. suis.  
10 Recommended age at first 
vaccination 
S19: Heifers 3-8 months of age.  
RB51: Heifers 4 - 10 months of age 
with 2 mℓ administered SC. 
Revaccinate with full dose 12 – 16 
months of age. 
Rev1: 4-6 months of age, 3 months for 
reduced dose 
From 1-2 months of age, when other 
vaccines are applied.  
11 Onset of immunity 
 
One week following primary vaccination 
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12 Duration of immunity 
 
At least 1 year 
 
Lifelong immunity 
13 Expected efficacy To prevent disease & prevent 
mortality. 
To prevent infection and transmission in 
100% of the animals. No disease & no 
mortality in vaccinated animals after 
virulent challenge. 
14 Expected safety Local reaction can occur at the site of 
injection. Mild temperature increase 
might occur.  
Risk of abortion in pregnant animals. 
Bulls: can cause persistent orchitis  
No post-vaccinal reactions at any age. 
Safe for pregnant animals at any stage.  
Safe for all sexes at any age.  
15 Withdrawal period 
 
S19: 
RB51:  3 weeks 
Rev1:  21 days meat, 90 days milk 
Nil for milk and meat 
16 Special requirements for 
animals 
Do not vaccinate un-healthy animals. 
Do not vaccinate pregnant animals or 
animals in lactation.  
Avoid antibiotic therapy before and 
after vaccination for a period of 21 
days.  
Vaccinate all animals 
17 Special requirements for 
persons 
Several as they are pathogenic for 
humans: 
Avoid direct contact. Do not eat, drink 
or smoke during administration of the 
vaccine.  
Burn or sterilize container after use.  
None 
18 Package size 
 
5-25 doses Multiple pack size from 5 doses 
19 Price to end user 
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20 Storage condition and 
shelf-life as packaged for 
sale 
Stable at 4-8°C for 12 months 
 
Stable at 30°C for 24 months 
 
21 In-use stability 
 
S19: 2 hours 
RB51:  
Rev1:  
24 hours or greater 
22 Other:  Interference with 
diagnostics 
Interfere with some (or all) available 
diagnostics 
Do not interfere with diagnostics 






There are many combinations that might be of interest. They will vary depending on the species and geography. 
For cattle, a combined vaccine with Tuberculosis could be of great value, especially for dairy on small holder 
farmer settings and cooperatives. FMD could also be considered.  
For small ruminants, combinations with any vaccine routinely used in the area, for example clostridium, could be 
of interest. Of public health importance is also hydatid disease.  
For pigs, it will really depend on the geography. In SE Asia, combination with FMD and CSF could be good. In 
Africa, pigs are rarely vaccinated. Ideally, any vaccine that could be combined with ASF would be of great value. 
From the public health point of view, combination with cysticercosis would be of value.   
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Scientific quality: The publications and data from the different research groups, should be carefully evaluated.  
The use of good science and good experimental design with use of proper controls, adequate numbers, suitable 
challenge model, reproduction of results by them and by independent groups, and appropriate analysis has not 
been verified for this monograph.  If any of these projects were to be pursued, a detailed peer review taking into 
account the above considerations is strongly recommended.   
Other considerations for vaccine improvement and development:  
1. The murine model is not as good model as it seems. Brucella is not a natural host and tends to produce 
splenic and liver colonisation in mice, while in the other animals affects mostly the lymphoreticular 
system. The responses of inbred strains of mice do not accurately reflect the immune responses of 
heterozygous livestock. It has previously been observed that data form murine models has failed to 
predict immunogenicity or efficacy of vaccines in domestic animals [88]. Attention should be given to 
vaccines evaluated in the target species.  
2. There is a lack of knowledge on protective epitopes.  It is not likely that a single epitope will produce a 
robust immune response. Vaccines expressing one epitope might not produce robust immunity. Some 
antigens have been identified with protection, but not all. The role of antibodies is not clearly known.  
3. The different species of Brucella have over 90% homology. Therefore, it is expected that many strains 
will give protection. However, it is important to evaluate what will work with a single dose, duration of 
immunity (in years), cost of delivery, etc..   
4. However, it is questionable if a Brucella ovis vaccine will protect across species as it is quite different, 
and there are some species limitations. For example, B. abortus in pigs tends to be cleared quickly.  
5. Many vaccines will work if there is an annual vaccination policy. The key point is which one provides 
better protection. A side by side analysis of the different vaccines would be very valuable.  For example, 
there is contradictory information about efficacy of the different vaccines for B. melitensis in cattle. A 
side by side comparison of the current vaccines (including S19, RB51, Rev1) with some of the most 
promising candidates (ideally the ones already evaluated in target species) for B. melitensis in cattle 
would be very valuable.  
6. Live vaccines prevent infection (and abortions), but they do not stop colonisation (shedding in milk in 
lactating animals).   
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ANNEX 1:  Additional data on disease presence and 
incidence 
 
Reports to OIE on Brucella abortus: 
 
 
When different animal health statuses between domestic and wild animal population are provided, the box is split in two: 
the upper part for domestic animals, and the lower part for wild animals.  
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Brucella abortus in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
 
Brucella abortus in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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Brucella abortus in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
Brucella melitensis in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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Brucella melitensis in Eastern Africa: Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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Brucella melitensis in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
Brucella suis in Asia: Bangladesh, India, Indonesia, Myanmar, Nepal and Vietnam 
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Brucella suis in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
 
 
Brucella suis in Eastern Africa: Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
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Brucella suis in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
 
 
 
 
 
